Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05736029 · ClinicalTrials.gov registry record
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
A clinical trial of Healthy and Non-Small Cell Lung Cancer, sponsored by OncoHost.
- Recruiting
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT05736029: Recruiting study of Healthy and Non-Small Cell Lung Cancer, sponsored by OncoHost.
NCT05736029 is a study of Healthy and Non-Small Cell Lung Cancer that is actively recruiting participants, run by OncoHost. The registered enrollment target is 350 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05736029, a study of Healthy and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by OncoHost.
- RECRUITING
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment, and clinical data will be collected.
Primary Outcome
OR as defined by RECIST 1.1 or any other validated clinical scale for response
Conditions Studied
Interventions
- OTHER blood, stool and tissue samples collection
Study Locations (1)
Texas
- Baylor Scott and White Research Institute - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2028-06-30 |
What NCT05736029 shows while recruiting
NCT05736029 is an observational study that tracks outcomes without assigning an intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which blood, stool and tissue samples collection is the first listed.
NCT05736029 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05736029 about?
NCT05736029 is a clinical study titled "Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics". The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing...
What is the current status of trial NCT05736029?
This trial is currently recruiting. The enrollment target is 350 participants. The study started on 2022-11-07. Estimated completion is 2028-06-30.
What conditions does trial NCT05736029 study?
This clinical trial studies the following conditions: Healthy, Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05736029?
The interventions under investigation include: blood, stool and tissue samples collection (OTHER).
Who is sponsoring clinical trial NCT05736029?
This trial is sponsored by OncoHost, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05736029 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05736029's enrollment target sits among peer trials
350 71st of 1090 higher than 1,020 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI